Clinical trials: Myocardial Ischaemia
Myocardial Infarction, Coronary Arteriosclerosis
Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction
The purpose of this study is to establish safety and feasibility of utilizing Adipose-Derived Stem and Regenerative Cells (ADRC's) in patients who have suffered a ST-elevation acute myocardial infarction.
- Conditions
- Myocardial Infarction, Coronary Arteriosclerosis, Cardiovascular Disease, Coronary Disease
- Trial name
- NCT00442806
- Testing
- Injection of ADRC's
- Where
- 2 sites in Netherlands, Spain
- Volunteers
- 14 people
- Sponsor
- Cytori Therapeutics
Coronary Restenosis
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following de novo stenting or following…
- Trial name
- SNAPIST-III (NCT00124943)
- Testing
- Nanoparticle Paclitaxel
- Volunteers
- 112 people
- Sponsor
- Celgene Corporation
Hypertension, Angina Pectoris
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin (Caduet® Combination Tablets) in daily medical practice will be examined.
- Conditions
- Hypertension, Angina Pectoris, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- NCT01107743
- Testing
- Amlodipine/Atorvastatin
- Volunteers
- 1,291 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Artery Disease
TAXUS PERSEUS Workhorse
The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo…
- Trial name
- PERSEUS WH (NCT00484315)
- Testing
- Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
- Where
- 90 sites in United States, Australia and 2 more
- Volunteers
- 1,264 people
- Sponsor
- Boston Scientific Corporation
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE China Registry:
To document the safety and overall clinical performance of the Resolute Zotarolimus-Eluting Coronary Stent System in a real-world patient population requiring stent implantation.
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- R-C Registry (NCT01243749)
- Where
- 6 sites in China
- Volunteers
- 1,800 people
- Sponsor
- Medtronic Vascular
Hypercholesterolemia, Atherosclerosis
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20…
- Conditions
- Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00651378
- Testing
- Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin
- Volunteers
- 87 people
- Sponsor
- Organon and Co
Coronary Arteriosclerosis
Scoreflex TRIO - Scoring PTCA Catheter
To evaluate the acute safety and device procedural success of the Scoreflex TRIO Scoring PTCA catheters versus Scoreflex NC Scoring PTCA catheters in subjects with stenotic coronary arteries during percutaneous coronary…
- Trial name
- NCT05929313
- Testing
- OrbusNeich Scoreflex TRIO, OrbusNeich Scoreflex NC
- Where
- 4 sites in China
- Volunteers
- 210 people
- Sponsor
- OrbusNeich
Coronary Heart Disease
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
This study will evaluate the potential of RO4607381 to reduce cardiovascular morbidity and mortality in stable coronary heart disease patients with recent Acute Coronary Syndrome (ACS) and evaluate the long term safety profile of…
- Trial name
- NCT00658515
- Testing
- Dalcetrapib (RO4607381), Evidence-based medical care for Acute Coronary Syndrome
- Where
- 1,089 sites in United States, Argentina and 27 more
- Volunteers
- 15,871 people
- Sponsor
- Hoffmann-La Roche
Hypercholesterolemia, Acute Coronary Syndrome
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
Primary Objective: To compare the efficacy of alirocumab (Praluent®) with standard of care (SoC) on coronary atheroma progression (percent change in normalized total atheroma volume [TAV]) after 9 months of treatment in…
- Trial name
- ODYSSEY J-IVUS (NCT02984982)
- Testing
- Alirocumab SAR236553, Atorvastatin, Rosuvastatin
- Where
- 39 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Sanofi
Periodontitis, Coronary Disease
Periodontal Therapy in a Primary Prevention of Cardiovascular Disease
Cardiovascular diseases (CVD) are still considered the main cause of mortality and morbidity all over the world. In the last years, efforts have been made to define more effective therapeutic and preventive strategies.Periodontal…
- Trial name
- NCT02081976
- Testing
- Integrated Care Group, Standard Care Group
- Where
- India
- Volunteers
- 57 people
- Sponsor
- Macmillan Research Group UK
Atherosclerosis, Hypercholesterolemia
Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)
This study will assess whether the daily co-administration of ezetimibe 10 mg with ongoing treatment of simvastatin 20 mg will be more effective than treatment with simvastatin 20 mg alone in further reducing LDL-C concentrations.
- Conditions
- Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease
- Trial name
- NCT00651274
- Testing
- Ezetimibe
- Volunteers
- 144 people
- Sponsor
- Organon and Co
Primary Hypercholesterolemia
Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
This study assessed the safety and efficacy of generic Rosuvastatin in reducing plasma low density lipoprotein (LDL) cholesterol in Lebanese adult patients (18 years or older) with dyslipidemia for both primary and secondary…
- Trial name
- NCT03516955
- Testing
- Rosuvastatin
- Volunteers
- 317 people
- Sponsor
- Hikma Pharmaceuticals LLC
Coronary Artery Disease
Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent
The purpose of the EVOLVE Trial is to assess the safety and performance of the everolimus-eluting Evolution stent for the treatment of a de novo atherosclerotic lesion of up to 28 mm in length in a native coronary artery 2.25 mm…
- Trial name
- Evolve (NCT01135225)
- Testing
- PROMUS(TM) Element (TM) Stent System, Evolution Stent System
- Where
- 29 sites in Australia, Belgium and 7 more
- Volunteers
- 291 people
- Sponsor
- Boston Scientific Corporation
Coronary Stenosis
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
The primary objective of this study is to compare the performance of SUPRAFLEX to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease.
- Trial name
- TALENT (NCT02870140)
- Testing
- SUPRAFLEX, XIENCE
- Where
- 23 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 1,435 people
- Sponsor
- ECRI bv
Coronary Stenosis
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
The study will enroll approximately 316 subjects with a wide spectrum of PCI indications (stable angina as well as ACS), who are considered to be at high risk of bleeding.
- Trial name
- NCT03877848
- Testing
- Percutaneous Coronary Intervention (PCI)
- Where
- Israel
- Volunteers
- 319 people
- Sponsor
- Medinol Ltd.
Graft Occlusion, Vascular, Coronary Restenosis
A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.
This research study is intended to evaluate the safety and effectiveness of 3 different doses of BO-653, an investigational inhibitor of LDL cholesterol oxidation, when given orally twice a day compared to placebo (an inactive…
- Conditions
- Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
- Trial name
- NCT00055510
- Testing
- BO-653
- Where
- 29 sites in United States
- Sponsor
- Chugai Pharma USA
Coronary Artery Disease
Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial
This prospective, consecutive enrolment, single-arm study will enroll up to 15 patients with single de novo, Type A lesions < 10 mm in length and located in a native coronary artery with a reference vessel diameter of 2.75 mm …
- Trial name
- NCT02086006
- Testing
- DESolve Novolimus Eluting Bioresorbable Coronary Scaffold
- Where
- 3 sites in Belgium, New Zealand
- Volunteers
- 16 people
- Sponsor
- Elixir Medical Corporation
Coronary Artery Disease
A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
A prospective, multi-center, single-blinded, randomized trial to assess the safety and efficacy of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) in treating patients with coronary artery disease compared…
- Trial name
- IRONMAN-II (NCT05206084)
- Testing
- Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS), Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
- Where
- China
- Volunteers
- 518 people
- Sponsor
- Biotyx Medical (Shenzhen) Co., Ltd.
Ischemic Heart Disease
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
This is a six (6) month, randomized, un-blinded, study to assess the safety and performance of the Palmaz Mach-5 Grooved Coronary Stent System vs. the Palmaz Bare Metal Coronary Stent System.
- Trial name
- NCT02759406
- Testing
- coronary stent
- Volunteers
- 48 people
- Sponsor
- Palmaz Scientific
Myocardial Infarction, Angina
An Observational Study of Cholesterol in Coronary Arteries
In April 2008, a coronary catheter based imaging system, LipiScan, was cleared by the FDA for use in detecting lipid core containing containing plaques of interest (LCP). These plaques are rich in cholesterol.
- Conditions
- Myocardial Infarction, Angina, Coronary Artery Disease, Myocardial Ischemia
- Trial name
- COLOR (NCT00831116)
- Testing
- Intravascular Near Infrared Spectroscopy
- Where
- 22 sites in United States
- Volunteers
- 2,067 people
- Sponsor
- Infraredx